恩帕吉菲
医学
二羟基化合物
糖尿病
魔法子弹
心力衰竭
内科学
心脏病学
2型糖尿病
内分泌学
生物信息学
生物
环氧树脂
有机化学
化学
双酚A
作者
K.G. Subramaniam,N.A. Mohd Yunus,Y.W. Lim,N.N.F. Sophian Basha,L. Nokarajoo,R.A.W. Raja Muhammad Rooshdi,A.N.L.C. Seng,M.M. Tan,N. Mansor,K.H. Chee,E. Mageswaren
标识
DOI:10.1016/j.ijcard.2022.10.053
摘要
The recent trials have shown that empagliflozin 10 mg is effective in reducing the risk of cardiovascular events and hospitalisation due to heart failure. In our local setting, the use of empagliflozin of 25 mg or 12.5 mg is more favourable due to ease of access.
科研通智能强力驱动
Strongly Powered by AbleSci AI